Clinical Trials
Keyword Search All Trials- Alzheimer's Disease Neuroimaging Initiative (ADNI)
- Coping Long Term with Suicide Program
- Mood Management Phone Counseling in Smoking Cessation
- Development of a Treatment Adherence Program for Bipolar Substance Abusers
- Behavioral Exercise Intervention for Smoking Cessation
- Motivational Interviewing for Teen Substance Use with Comorbid Psychiatric Disorder
- Fluoxetine Smoking Cessation Study
- Pharmacotherapy Relapse Prevention in Body Dysmorphic Disorder
- Fluoxetine in Pediatric Body Dysmorphic Disorder
- Development of a Psychosocial Treatment for Psychotic Depression
- A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety trial of bapineuzumab in patients with mild to moderate Alzheimer's disease.
- Phase IIa, multicenter, randomized, third-party unblinded, adjuvant and placebo-controlled, multiple ascending dose, safety, tolerability and immunogenicity trial of ACC-001 and QS-21 adjuvant in subjects with mild to moderate Alzheimer’s Disease
- Obsessive Compulsive Genetics Association Study
- Effectiveness of Deep Brain Stimulation for Treating People With Treatment Resistant Obsessive-Compulsive Disorder
- BMS CN156-013 - Oral Medication Trial for Mild to Moderate Alzheimer's Disease
- ELN115727-301/302 - Intraveneous Medication Trial for Mild to Moderate Alzheimer's disease
- DIM18 - Oral Medication Trial for Mild to Moderate Alzheimer's Disease
- Wyeth 3134K1-2201 - Intramuscular Medication Trial for Mild to Moderate Alzheimer's Disease
- Pfizer A9951002 - Intraveneous Medication Trial for Mild to Moderate Alzheimer's Disease
- Wyeth 3133L1-2203 - Subcutaneous Medication Trial for Mild to Moderate Alzheimer's Disease
- ADC-034 - Dominantly Inherited Alzheimer’s Network (DIAN)
- CN156-018 - Oral Medication Trial for Prodromal Alzheimer's Disease